Abundance Wealth Counselors Sells 1,404 Shares of GSK plc (NYSE:GSK)

Abundance Wealth Counselors reduced its stake in GSK plc (NYSE:GSK) by 6.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,011 shares of the pharmaceutical company’s stock after selling 1,404 shares during the quarter. Abundance Wealth Counselors’ holdings in GSK were worth $711,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Eastern Bank acquired a new position in shares of GSK in the third quarter valued at approximately $26,000. Sunbelt Securities Inc. increased its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Crews Bank & Trust bought a new stake in shares of GSK during the 4th quarter worth approximately $26,000. Concord Wealth Partners raised its holdings in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares in the last quarter. Finally, ST Germain D J Co. Inc. grew its holdings in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK stock opened at $35.20 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The firm has a 50 day moving average of $34.07 and a 200-day moving average of $37.69. The company has a market cap of $72.96 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63.

Wall Street Analyst Weigh In

GSK has been the subject of several research reports. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.